Australia's most trusted
source of pharma news
Monday, 16 September 2024
Posted 6 February 2024 AM
For the first time Vertex has taken first place in the annual top earners list, crushing 2023 with its triple-combination cystic fibrosis drug Trikafta earning a whopping $521.9 million pre-rebate on the R/PBS.
That represents an 80 per cent growth on what it earned for the full year 2022, although it only listed on 1 April of that year after an intense negotiation with the Department of Health.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.